Anti-TNFα therapy and risk of cancer in patients with immune-mediated diseases episode artwork

EPISODE · Jan 31, 2020 · 4 MIN

Anti-TNFα therapy and risk of cancer in patients with immune-mediated diseases

from Listen to The Lancet Gastroenterology & Hepatology · host The Lancet

Dr Akbar Waljee discusses findings from a cohort study investigating the risk of cancer recurrence or a new primary cancer in patients with IBD, rheumatoid arthritis, or psoriasis who received anti-TNFα therapy.

NOW PLAYING

Anti-TNFα therapy and risk of cancer in patients with immune-mediated diseases

0:00 4:08

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Gastroenterology & Hepatology?

This episode is 4 minutes long.

When was this Listen to The Lancet Gastroenterology & Hepatology episode published?

This episode was published on January 31, 2020.

What is this episode about?

Dr Akbar Waljee discusses findings from a cohort study investigating the risk of cancer recurrence or a new primary cancer in patients with IBD, rheumatoid arthritis, or psoriasis who received anti-TNFα therapy.

Can I download this Listen to The Lancet Gastroenterology & Hepatology episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!